Elevated liver function tests in type 2 diabetes

Clinical Diabetes

Volumn 23, Issue 3, 2005, Pages 115-119

  Harris, Elizabeth H ^a  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; GLIBENCLAMIDE; GLUCOSE; INSULIN; METFORMIN; ROSIGLITAZONE; STEROL REGULATORY ELEMENT BINDING PROTEIN; SULFONYLUREA; TRIACYLGLYCEROL; TROGLITAZONE; TUMOR NECROSIS FACTOR ALPHA; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALCOHOL LIVER DISEASE; ALKALINE PHOSPHATASE BLOOD LEVEL; DIET RESTRICTION; DOWN REGULATION; GLUCONEOGENESIS; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; HEPATOMEGALY; HUMAN; HYPERGLYCEMIA; HYPERINSULINEMIA; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; LIVER FAILURE; LIVER FUNCTION; LIVER FUNCTION TEST; LIVER INJURY; LIVER MITOCHONDRION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; PATHOPHYSIOLOGY; PATIENT MONITORING; POSTPRANDIAL STATE; PREDICTION; REVIEW; TRIACYLGLYCEROL BLOOD LEVEL; UPREGULATION; VIRUS HEPATITIS;

EID: 23744454350     PISSN: 08918929     EISSN: None     Source Type: Journal    
DOI: 10.2337/diaclin.23.3.115     Document Type: Review

References (28)

1. Lewis GF, Carpentier A, Khosrow A, Giacca A: Disordered fat storage and mobilization in the pathogenesis of insulin resistance and type 2 diabetes. Endocr Rev 23:201-229, 2002
2. Shimomura I, Matsuda M, Hammer RE, Bashmakov Y, Brown MS, Goldstein JL: Decreased IRS-2 and increased SREBP-1c lead to mixed insulin resistance and sensitivity in livers of lipodystrophic and ab/ab mice. Mol Cell 6:77-86, 2000
3. Neuschwander-Tetri BA, Caldwell S: Nonalcoholic steatohepatitis: summary of AASLD single topic conference. Hepatology 37:1202-1219, 2003
4. Grove J, Daly AK, Bassendine MF, Day CP: Association of a tumor necrosis factor promoter polymorphism with susceptibility to alcoholic steatohepatitis. Hepatology 26:143-146, 1997
5. O'Brien RM, Granner DK: Regulation of gene expression by insulin. Biochem J 278:609-619, 1991
6. Wannamethee G, Ebrahim S, Shaper AG: Gamma-glutamyltransferase: determinants and associations with mortality from ischaemic heart disease and all causes. Am J Epidemiol 42:699-708, 1995
7. Perry IJ, Wannamethee SG, Shaper AG: Prospective study of serum gamma-glutamyltransferase and risk of NIDDM. Diabetes Care 21:732-737, 1998
8. Ohlson LO, Larsson B, Bjorntorp P, Erksson H, Svardsudd K, Welin L, Tibblin G, Wilhelmsen L: Risk factors for type 2 diabetes mellitus: thirteen and one-half years of follow-up of the participants in a study of Swedish men born in 1913. Diabetologia 31:798-305, 1988
9. Vozarova B, Stefan N, Lindsay RS, Saremi A, Pratley RE, Bogardus C, Tataranni PA: High alanine aminotransferases is associated with decreased hepatic insulin sensitivity and predicts the development of type 2 diabetes. Diabetes 51:1889-1895, 2002
10. Salmela PI, Sotaniemi EA, Niemi M, Maentausta O: Liver function tests in diabetic patients. Diabetes Care 7:248-254, 1984
11. Erbey JR, Silberman C, Lydick E: Prevalence of abnormal serum alanine aminotransferase levels in obese patients and patients with type 2 diabetes. Am J Med 109:588-590, 2000
12. Alba LM, Lindor K: Review Article: Nonalcoholic fatty liver disease. Aliment Pharmacol Ther 17:977-986, 2003
13. Daniel S, Ben-Menachem T, Vasudevan G, Ma D, Blumenkehl M: Prospective evaluation of unexplained chronic liver transaminase abnormalities in asymptomatic and symptomatic patients. Am J Gastroenterol 94:3010-3014, 1999
14. Skelly MM, James PD, Ryder SD: Findings on liver biopsy to investigate abnormal liver function tests in the absence of diagnostic serology. J Hepatol 35:195-199, 2001
15. Baig NA, Herrine SK, Rubin R: Liver disease and diabetes mellitus. Clin Lab Med 21:193-207, 2001
16. Knobler H, Schihmanter R, Zifroni A, Finakel G, Schattner A: Increased risk of type 2 diabetes in noncirrhotic patients with chronic hepatitis C virus infection. Mayo Clin Proc 75:355-359, 2000
17. Simo R, Hernandez C, Genesca J, Jardi R, Mesa J: High prevalence of hepatitis C virus infection in diabetic patients. Diabetes Care 19:998-1000, 1996
18. Heart Protection Study Collaborative Group: MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomized placebo-controlled trial. Lancet 360:7-22, 2002
19. Shepherd J, Blauw GJ, Murphy MB, Bollen EL, Buckley BM, Cobbe SM, Ford I, Gaw A, Hyland M, Jukema JW, Kamper AM, Macfarlane PW, Meinders AE, Norrie J, Packard CJ, Perry IJ, Stott DJ, Sweeney BJ, Twomey C, Westendorp RG, the PROSPER study group: Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomized controlled trial. Lancet 360:1623-1630, 2002
20. LaRosa JC, Grundy SM, Waters DD, Shear C, Barter P, Fruchart JC, Gotto AM, Greten H, Kastelein JJ, Shepherd J, Wenger NK, the Treating to New Targets (TNT) Investigators: Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 352:1425-1435, 2005
21. Snow V, Aronson M, Hornbake R, Mottur-Pilson C, Weiss K: Lipid control in the management of type 2 diabetes mellitus: a clinical practice guideline from the American College of Physicians. Ann Intern Med 140:644-650, 2004
22. Pasternak RC, Smith SC Jr, Bairey-Merz CN, Grundy SM, Cleeman JI, Lenfant C, for the American College of Cardiology, American Heart Association and National Heart, Lung and Blood Institute: ACC/AHA/NHLBI clinical advisory on the use and safety of statins. Stroke 33:2337-2341, 2002
23. Jick SS, Stender M, Myers M: Frequency of liver disease in type 2 diabetic patients treated with oral antidiabetic agents. Diabetes Care 22:2067-2071, 1999
24. Rajagopalan R, Iyer S, Perez A: Comparison of pioglitazone with other antidiabetic drugs for associated incidence of liver failure: no evidence of increased risk of liver failure with pioglitazone. Diabetes Obes Metab 7:161-169, 2005
25. ACTOS Prescribing Information [article online]. Lincolnshire, Ill., Takeda Pharmaceuticals North America, 2003. Available from http://www.actos.com/ pi.pdf
26. Lebovitz H, Kreider M, Freed M: Evaluation of liver function in type 2 diabetic patients during clinical trials: evidence that rosiglitazone does not cause hepatic dysfunction. Diabetes Care 25:815-821, 2002
27. Promrat K, Lutchman G, Uwaifo GI, Freedman RJ, Soza A, Heller T, Doo E, Ghany M, Premkumar A, Park Y, Liang TJ, Yanovski J, Kleiner D, Hoofnagle JH: A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis. Hepatology 39:188-195, 2003
28. Neushwander-Tetri BA, Brunt EM, Wehmeier KR, Oliver D, Bacon BR: Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR gamma ligand rosiglitazone. Hepatology 38:1008-1016, 2004